130 related articles for article (PubMed ID: 25600474)
1. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
3. Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures.
Lin SY; Chen WJ; Ku CK; Chen YM; Chen CH; Chien LN
J Clin Endocrinol Metab; 2023 Dec; 109(1):e200-e208. PubMed ID: 37526298
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.
Chattaris T; Oh G; Gouskova NA; Kim DH; Kiel DP; Berry SD
J Bone Miner Res; 2022 Nov; 37(11):2103-2111. PubMed ID: 36168189
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes.
Casagrande SS; Cowie CC; Malozowski S
J Diabetes Complications; 2017 Feb; 31(2):353-357. PubMed ID: 27431890
[TBL] [Abstract][Full Text] [Related]
6. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Imano H; Ogawa S
Osteoporos Int; 2024 May; 35(5):805-818. PubMed ID: 38267664
[TBL] [Abstract][Full Text] [Related]
7. Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids.
Billups SJ; Thai VK; Denkins J; Dettman IC; Rothman MS
Arch Osteoporos; 2023 Mar; 18(1):38. PubMed ID: 36856881
[TBL] [Abstract][Full Text] [Related]
8. Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis.
Wang CY; Wu CH; Chen HM; Lin JW; Hsu CC; Chang YF; Tai TW; Fu SH; Hwang JS
J Formos Med Assoc; 2023; 122 Suppl 1():S92-S100. PubMed ID: 37574339
[TBL] [Abstract][Full Text] [Related]
9. Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme.
Safavi R; Lih A; Kirkpatrick S; Haller S; Bailony MR
Obes Sci Pract; 2019 Oct; 5(5):468-478. PubMed ID: 31687171
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease.
Rahman A; Haider MF
Steroids; 2024 May; 207():109440. PubMed ID: 38754651
[TBL] [Abstract][Full Text] [Related]
11. Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort.
Einarsdottir MJ; Kibiwott Kirui B; Li H; Olsson D; Johannsson G; Nyberg F; Ragnarsson O
BMJ Open; 2024 Mar; 14(3):e080640. PubMed ID: 38490654
[TBL] [Abstract][Full Text] [Related]
12. Oral Glucocorticoid Use and Long-Term Mortality in Patients with Chronic Musculoskeletal Non-Cancer Pain: A Cross-Sectional Cohort Study.
Choi HR; Song IA; Oh TK
Diagnostics (Basel); 2023 Jul; 13(15):. PubMed ID: 37568884
[TBL] [Abstract][Full Text] [Related]
13. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.
Brock GR; Chen JT; Ingraffea AR; MacLeay J; Pluhar GE; Boskey AL; van der Meulen MC
Bone Rep; 2015 Jun; 2():8-13. PubMed ID: 25642445
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone therapy for hypoparathyroidism.
Cusano NE; Rubin MR; Bilezikian JP
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):47-55. PubMed ID: 25617172
[TBL] [Abstract][Full Text] [Related]
16. Improvement of skeletal fragility by teriparatide in adult osteoporosis patients: a novel mechanostat-based hypothesis for bone quality.
Sugiyama T; Torio T; Sato T; Matsumoto M; Kim YT; Oda H
Front Endocrinol (Lausanne); 2015; 6():6. PubMed ID: 25688232
[No Abstract] [Full Text] [Related]
17. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.
Whitmarsh T; Treece GM; Gee AH; Poole KE
J Bone Miner Res; 2015 Jul; 30(7):1309-18. PubMed ID: 25639838
[TBL] [Abstract][Full Text] [Related]
18. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the treatment of osteoporosis.
Zaheer S; LeBoff M; Lewiecki EM
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):461-70. PubMed ID: 25614274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
